IP Library › Granted Patent US 10,815,266
Granted Patent B2
US 10,815,266 · App. 16/278,621 · Granted Oct 27, 2020

β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N

Inventors: Jean-Pierre Sommadossi (Boston, MA); Adel Moussa (Burlington, MA)
Assignee: Atea Pharmaceuticals, Inc.
C07H19/207A61K31/7076A61P31/14C07H19/16C07H19/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,815,266
App. No.
16/278,621
Granted
Oct 27, 2020
Kind
B2
Abstract

A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Claims (4)

1. A compound of the formula:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 of the formula:

or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2019
From: SOMMADOSSI, JEAN-PIERRE; MOUSSA, ADEL
To: ATEA PHARMACEUTICALS, INC.
Reel/Frame 049536/0911 →
Continuity (7)
Continuation 16001549 · Jun 6, 2018
Continuation 15782628 · Oct 12, 2017
Continuation 15063461 · Mar 7, 2016
Provisional Application 62276597 · Jan 8, 2016
Provisional Application 62253958 · Nov 11, 2015
Provisional Application 62129319 · Mar 6, 2015
Related Publication 20190177356A1 · Jun 13, 2019
Cited By (2)
US 12,458,656 US 12,551,499